Open | - |
Close | - |
Volume / Avg. | 0 / 1.699M |
Day Range | - - - |
52 Wk Range | 50.270 - 76.040 |
Market Cap | $13.023B |
P/E Ratio | 21.638 |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 44 |
Short Interest | 4.64% |
Days to Cover | 4.84 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Incyte (NASDAQ: INCY) through any online brokerage.
Other companies in Incyte’s space includes: Legend Biotech (NASDAQ:LEGN), Sarepta Therapeutics (NASDAQ:SRPT), Exact Sciences (NASDAQ:EXAS), Neurocrine Biosciences (NASDAQ:NBIX) and Cerevel Therapeutics Hldg (NASDAQ:CERE).
The latest price target for Incyte (NASDAQ: INCY) was reported by B of A Securities on Wednesday, March 13, 2024. The analyst firm set a price target for 67.00 expecting INCY to rise to within 12 months (a possible 15.52% upside). 44 analyst firms have reported ratings in the last year.
The stock price for Incyte (NASDAQ: INCY) is $58 last updated March 18, 2024 at 7:05 PM EDT.
There are no upcoming dividends for Incyte.
Incyte’s Q1 earnings are confirmed for Tuesday, April 30, 2024.
There is no upcoming split for Incyte.
Incyte is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.